

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2563)

VOLUNTARY ANNOUNCEMENT

INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This announcement is made by Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to announce that on 6 May 2026, the Board has resolved to repurchase the H shares of the Company (the “**H Shares**”) in the open market from time to time, subject to foreign exchange remittance approval with the relevant regulatory authorities in the People's Republic of China (the “**PRC**”) and necessary shareholders' approval for certain proposed amendments to the articles of association of the Company (the “**Articles of Association**”) in relation to share repurchases.

At the annual general meeting of the Company convened and held on 25 August 2025 (the “**2025 AGM**”), the Directors were granted with the general and unconditional mandate to repurchase H Shares not exceeding 10% of the total number of H Shares in issue as at the date of the AGM (the “**2025 Repurchase Mandate**”).

The Company shall conduct the repurchases by exercising its powers under the 2025 Repurchase Mandate, and in compliance with the Articles of Association, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, The Codes on Takeovers and Mergers and Share Buy-backs, the Company Law of the PRC, and all applicable laws and regulations to which the Company is subject.

The Company believes that a share repurchase in the present conditions will demonstrate the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to its shareholders. The Board believes that the current financial resources of the Company would enable it to implement the share repurchase while maintaining a solid financial position.

Shareholders of the Company and potential investors should note that the implementation of the on-market share repurchase by the Company will be subject to market conditions and will be at the absolute discretion of the Board and/or its authorized person(s). There is no assurance of the timing, quantity or price of any repurchases or whether the Company will make any repurchases at all. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairman and Executive Director

Beijing, the PRC, 7 May 2026

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.